BACKGROUND AND PURPOSE: Drinking caffeinated coffee has been reported to provide protection against Parkinson's disease (PD). Caffeine is an adenosine A2A receptor (encoded by the gene ADORA2A) antagonist that increases dopaminergic neurotransmission and Cytochrome P450 1A2 (gene: CYP1A2) metabolizes caffeine; thus, gene polymorphisms in ADORA2A and CYP1A2 may influence the effect coffee consumption has on PD risk. METHODS: In a population-based case-control study (PASIDA) in Denmark (1,556 PD patients and 1,606 birth year- and gender-matched controls), we assessed interactions between lifetime coffee consumption and 3 polymorphisms in ADORA2A and CYP1A2 for all subjects, and incident and prevalent PD cases separately using logistic regression models. We also conducted a meta-analysis combining our results with those from previous studies. RESULTS: We estimated statistically significant interactions for ADORA2A rs5760423 and heavy vs. light coffee consumption in incident (OR interaction = 0.66 [95% CI 0.46-0.94], p = 0.02) but not prevalent PD. We did not observe interactions for CYP1A2 rs762551 and rs2472304 in incident or prevalent PD. In meta-analyses, PD associations with daily coffee consumption were strongest among carriers of variant alleles in both ADORA2A and CYP1A2. CONCLUSION: We corroborated results from a previous report that described interactions between ADORA2A and CYP1A2 polymorphisms and coffee consumption. Our results also suggest that survivor bias may affect results of studies that enroll prevalent PD cases.
BACKGROUND AND PURPOSE: Drinking caffeinated coffee has been reported to provide protection against Parkinson's disease (PD). Caffeine is an adenosine A2A receptor (encoded by the gene ADORA2A) antagonist that increases dopaminergic neurotransmission and Cytochrome P450 1A2 (gene: CYP1A2) metabolizes caffeine; thus, gene polymorphisms in ADORA2A and CYP1A2 may influence the effect coffee consumption has on PD risk. METHODS: In a population-based case-control study (PASIDA) in Denmark (1,556 PDpatients and 1,606 birth year- and gender-matched controls), we assessed interactions between lifetime coffee consumption and 3 polymorphisms in ADORA2A and CYP1A2 for all subjects, and incident and prevalent PD cases separately using logistic regression models. We also conducted a meta-analysis combining our results with those from previous studies. RESULTS: We estimated statistically significant interactions for ADORA2Ars5760423 and heavy vs. light coffee consumption in incident (OR interaction = 0.66 [95% CI 0.46-0.94], p = 0.02) but not prevalent PD. We did not observe interactions for CYP1A2rs762551 and rs2472304 in incident or prevalent PD. In meta-analyses, PD associations with daily coffee consumption were strongest among carriers of variant alleles in both ADORA2A and CYP1A2. CONCLUSION: We corroborated results from a previous report that described interactions between ADORA2A and CYP1A2 polymorphisms and coffee consumption. Our results also suggest that survivor bias may affect results of studies that enroll prevalent PD cases.
Authors: J F Chen; K Xu; J P Petzer; R Staal; Y H Xu; M Beilstein; P K Sonsalla; K Castagnoli; N Castagnoli; M A Schwarzschild Journal: J Neurosci Date: 2001-05-15 Impact factor: 6.167
Authors: E K Tan; Z Y Lu; S M C Fook-Chong; E Tan; H Shen; E Chua; Y Yih; Y Y Teo; Y Zhao Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2006-09-05 Impact factor: 3.568
Authors: W Hellenbrand; A Seidler; H Boeing; B P Robra; P Vieregge; P Nischan; J Joerg; W H Oertel; E Schneider; G Ulm Journal: Neurology Date: 1996-09 Impact factor: 9.910
Authors: Taye H Hamza; Honglei Chen; Erin M Hill-Burns; Shannon L Rhodes; Jennifer Montimurro; Denise M Kay; Albert Tenesa; Victoria I Kusel; Patricia Sheehan; Muthukrishnan Eaaswarkhanth; Dora Yearout; Ali Samii; John W Roberts; Pinky Agarwal; Yvette Bordelon; Yikyung Park; Liyong Wang; Jianjun Gao; Jeffery M Vance; Kenneth S Kendler; Silviu-Alin Bacanu; William K Scott; Beate Ritz; John Nutt; Stewart A Factor; Cyrus P Zabetian; Haydeh Payami Journal: PLoS Genet Date: 2011-08-18 Impact factor: 5.917
Authors: Ismaïl Ahmed; Pei-Chen Lee; Christina M Lill; Susan Searles Nielsen; Fanny Artaud; Lisa G Gallagher; Marie-Anne Loriot; Claire Mulot; Magali Nacfer; Tian Liu; Joanna M Biernacka; Sebastian Armasu; Kari Anderson; Federico M Farin; Christina Funch Lassen; Johnni Hansen; Jørgen H Olsen; Lars Bertram; Demetrius M Maraganore; Harvey Checkoway; Beate Ritz; Alexis Elbaz Journal: PLoS Genet Date: 2014-11-20 Impact factor: 5.917
Authors: Iris Y Kim; Éilis J O'Reilly; Katherine C Hughes; Xiang Gao; Michael A Schwarzschild; Marjorie L McCullough; Marian T Hannan; Rebecca A Betensky; Alberto Ascherio Journal: Mov Disord Date: 2018-01-10 Impact factor: 10.338
Authors: Hanan Khalil; Lana M Chahine; Junaid Siddiqui; Mehri Salari; Shaimaa El-Jaafary; Zakiyah Aldaajani; Mishal Abu Al-Melh; Tareq Mohammad Mohammad; Muneer Abu Snineh; Nadir A Syed; Mohit Bhatt; Mohammad Ahsan Habib; Majed Habahbeh; Samer D Tabbal; Beomseok Jeon; Jawad A Bajwa Journal: J Parkinsons Dis Date: 2020 Impact factor: 5.568
Authors: Vikki Houghton; Andrea Du Preez; Sophie Lefèvre-Arbogast; Chiara de Lucia; Dorrain Y Low; Mireia Urpi-Sarda; Silvie R Ruigrok; Barbara Altendorfer; Raúl González-Domínguez; Cristina Andres-Lacueva; Ludwig Aigner; Paul J Lucassen; Aniko Korosi; Cécilia Samieri; Claudine Manach; Sandrine Thuret Journal: Front Cell Dev Biol Date: 2020-09-08